Trubion raises $32 million

Trubion (Seattle, Wash.) raised $32 million in a series B round co-led by Prospect and Venrock. Other investors in the inflammatory disease and cancer company included Arch; Frazier; Oxford Bioscience; and ATP Capital. David Schnell, a managing director of Prospect, and Anders Hove, a general partner of Venrock, will join Trubion's board. ...